SipNose
Intranasal Drug-delivery Platform
Company Overview
Snapshot
Founded in November 2011 by Daniel Shahaf, SipNose operates with 1-10 employees. The company was acquired by Aptar Pharma in October 2024.
Business overview
SipNose develops an intranasal drug-delivery platform for local, systemic, and central nervous system indications. The company's core technology focuses on noninvasive devices designed to ensure accurate dose delivery via the nasal cavity, enabling better absorption into the olfactory bulb and brain. This platform facilitates faster and more efficient delivery of drug molecules with diverse chemical and pharmaceutical characteristics, serving markets within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals, biotechnology, and healthcare providers.
Strategic signal
In October 2024, SipNose was acquired by Aptar Pharma for approximately $12.5 million. This acquisition validates SipNose's innovative nasal drug delivery technology, which targets specific areas of the nasal cavity for non-invasive drug delivery to the brain. The deal signals a growth-positive trajectory for SipNose's technology and highlights the increasing strategic interest in advanced drug delivery systems within the pharmaceutical industry.
Log in to access full profile ›Company Intelligence Q&A
- What was the most significant corporate event for SipNose recently?
- In October 2024, SipNose was acquired by Aptar Pharma for approximately $12.5 million. This acquisition included the device technology assets of SipNose.
- Who founded SipNose?
- SipNose was founded by Daniel Shahaf.
- What is SipNose's core technology?
- SipNose's core technology is an intranasal drug-delivery platform that uses a mechanism designed to improve efficacy, patient compliance, and safety by ensuring accurate dose delivery via the nasal cavity for better absorption into the olfactory bulb and brain.
- When was SipNose founded?
- SipNose was founded in November 2011.
- Did SipNose engage in any commercial partnerships?
- In June 2021, SipNose Ltd. and Noveome Biotherapeutics, Inc. announced a commercial license agreement for the SipNose Cribriform Targeted Device.